Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Browse by All Cardiff Authors

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Number of items: 5.

Jones, Ashley T., Yang, Jian, Narov, Kalin, Henske, Elizabeth P, Sampson, Julian R. and Shen, Ming Hong 2019. Allosteric and ATP-competitive inhibitors of mTOR effectively suppress tumor progression-associated epithelial-mesenchymal transition in the kidneys of Tsc2+/− Mice. Neoplasia 21 (8) , pp. 731-739. 10.1016/j.neo.2019.05.003

Jones, Ashley T., Narov, Kalin, Yang, Jian, Sampson, Julian R. and Shen, Ming Hong 2019. Efficacy of dual inhibition of glycolysis and glutaminolysis for therapy of renal lesions in Tsc2+/− Mice1. NEOPLASIA 21 (2) , pp. 230-238. 10.1016/j.neo.2018.12.003

Shen, Ming, Samsel, Paulina, Shen, Louise L., Narov, Kalin, Yang, Jian and Sampson, Julian 2017. Assessment of response of kidney tumours to rapamycin and atorvastatin in Tsc1+/- mice. Translational Oncology 10 (5) , pp. 793-799. 10.1016/j.tranon.2017.07.009

Narov, Kalin, Yang, Jian, Samsel, Paulina, Jones, Ashley, Sampson, Julian R and Shen, Ming Hong 2017. The dual PI3K/mTOR inhibitor GSK2126458 is effective for treating solid renal tumours in Tsc2+/- mice through suppression of cell proliferation and induction of apoptosis. Oncotarget , 17215. 10.18632/oncotarget.17215

Yang, Jian, Samsel, Paulina A., Narov, Kalin, Jones, Ashley, Gallacher, Daniel, Gallacher, John, Sampson, Julian Roy and Shen, Ming Hong 2017. Combination of everolimus with sorafenib for solid renal tumours in Tsc2+/- mice is superior to everolimus alone. Neoplasia 19 (2) , pp. 112-120. 10.1016/j.neo.2016.12.008

This list was generated on Wed Oct 21 06:32:06 2020 BST.